Sarepta offers Exondys 51 outside of the U.S. through a managed access program run by Clinigen, as an EMA decision is expected next year.
Telix has committed about $65 million in return for the exclusive right to use the antibodies to guide radioactive payloads to tumors.
South Korean, Celltrion group is a global leader for biologic medicine and is a pioneer in the approval of biosimilar profile in Europe, US and Brazil. The…
Science Exchange will offer IndieBio-backed biotech startups access to its outsourced R&D platform.
It’s time again to call on you to nominate your Fierce 15 for 2017.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Clinigen has signed exclusive agreements with Mitsubishi Tanabe, Shionogi and Romark to cooperate on expanded access to their medicines.
Clinical trial supporting platform MyClin just launched Clinical Works, a set of services that designs highly engaging materials to streamline trials.
Two years out from the U.K.'s scheduled EU exit date, the life science sector is increasingly confident about its post-Brexit prospects.
Astellas Pharma has struck a drug discovery deal worth up to $100 million per target with X-Chem.
Nonprofit Parkinson’s UK has teamed up with the University of Sheffield to create a virtual biotech.
Bioversys has enlisted Aptuit to support its efforts to identify and validate novel targets and drugs against Gram-negative bacteria.